A liaF Codon Deletion Abolishes Daptomycin Bactericidal Activity against Vancomycin-Resistant Enterococcus faecalis
Open accessAbstract
The genetic bases for antibiotic tolerance are obscure. Daptomycin (DAP) is a lipopeptide antibiotic with bactericidal activity against enterococci. Using time-kill assays, we provide evidence for the first time that a deletion of isoleucine in position 177 of LiaF, a member of the three-component regulatory system LiaFSR involved in the cell envelope response to antimicrobials, is directly responsible for a DAP-tolerant phenotype and is likely to negatively affect response to DAP therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A single deletion of an isoleucine at position 177 of LiaF increased the DAP MIC from 1 to 4 μg/mL and was sufficient to abolish the bactericidal activity of DAP.
“Indeed, a single deletion of an isoleucine at position 177 of LiaF increased the DAP MIC from 1 to 4 μg/mL (established clinical breakpoint is 4 μg/ml) and, more importantly, was sufficient to abolish the bactericidal activity of DAP (89).”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Management of multidrug-resistant enterococcal infections
Arias, C. A., Contreras, G., & Murray, B. E. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03214.x · Cited by 384 · see citing works
Self-citationGenetic Basis for In Vivo Daptomycin Resistance in Enterococci
Arias, C. A., Panesso, D., McGrath, D. M., Qin, X., Mojica, M. F., Miller, C., Diaz, L., Tran, T. T., Rincon, S., Barbu, E. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011138 · Cited by 377 · see citing works
Self-citationEmergence of Daptomycin Resistance in Enterococcus faecium during Daptomycin Therapy
Sabol, K., PATTERSON, J. E., Lewis, J. S., Owens, A. D., Cadena, J., & Jorgensen, J. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1664-1665.2005 · Cited by 209 · see citing works
Munoz-Price, L. S., Lolans, K., & Quinn, J. P. (2005) · Clinical Infectious Diseases · doi:10.1086/432121 · Cited by 157 · see citing works
Galloway-Peña, J., Roh, J. H., Latorre, M., Qin, X., & Murray, B. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030187 · Cited by 148 · see citing works
Self-citationThe LiaFSR System Regulates the Cell Envelope Stress Response inStreptococcus mutans
Suntharalingam, P., Senadheera, M. D., Mair, R. W., Levesque, C. M., & Cvitkovitch, D. G. (2009) · Journal of Bacteriology · doi:10.1128/jb.01563-08 · Cited by 141 · see citing works
Munita, J. M., Panesso, D., Diaz, L., Tran, T. T., Reyes, J., Wanger, A., Murray, B. E., & Arias, C. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00509-12 · Cited by 118 · see citing works
Self-citationHall, A. D., Steed, M. E., Arias, C. A., Murray, B. E., & Rybak, M. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06439-11 · Cited by 101 · see citing works
Self-citationArias, C. A., Torres, H. A., Singh, K. V., Panesso, D., Moore, J. E., Wanger, A. R., & Murray, B. E. (2007) · Clinical Infectious Diseases · doi:10.1086/522656 · Cited by 84 · see citing works
Self-citationEldholm, V., Gutt, B., Johnsborg, O., Brückner, R., Maurer, P., Hakenbeck, R., Mascher, T., & Håvarstein, L. S. (2010) · Journal of Bacteriology · doi:10.1128/jb.01489-09 · Cited by 63 · see citing works
De Novo Daptomycin-Nonsusceptible Enterococcal Infections
Kelesidis, T., Humphries, R. M., Uslan, D. Z., & Pegues, D. A. (2012) · Emerging infectious diseases · doi:10.3201/eid1804.110932 · Cited by 43 · see citing works
Schwartz, B. S., Ngo, P. D., & Guglielmo, B. J. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k548 · Cited by 33 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Mechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782 · see citing works
“Indeed, a single deletion of an isoleucine at position 177 of LiaF increased the DAP MIC from 1 to 4 μ g/ml (established clinical breakpoint is 4 μ g/ml) and, more importantly, was suf fi cient to abolish the bactericidal activity of DAP (89).”
BackgroundSelf-citationMechanisms of antibiotic resistance in enterococci
Miller, W. R., Munita, J. M., & Arias, C. A. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.956092 · Cited by 772 · see citing works
“More importantly, these changes were sufficient to abolish the in vitro bactericidal activity of DAP [60] and were associated with a clinical failure in a neutropenic patient with VRE bacteremia [70].”
BackgroundSelf-citationBacterial stress responses as determinants of antimicrobial resistance
Poole, K. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks196 · Cited by 515 · see citing works
Mechanisms of antibiotic resistance
Munita, J. M., & Arias, C. A. (2016) · Virulence Mechanisms of Bacterial Pathogens · doi:10.1128/9781555819286.ch17 · Cited by 421 · see citing works
Self-citationBender, J. K., Cattoir, V., Hegstad, K., Sadowy, E., Coque, T. M., Westh, H., Hammerum, A. M., Schaffer, K., Burns, K., Murchan, S., et al. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.10.002 · Cited by 281 · see citing works
“High levels of MICs can be reached when additional mutations occur in gdpD and cls that alter the phospholipid content of the cell membrane (Arias et al., 2011; Mishra et al., 2012; Munita et al., 2013; Reyes et al., 2015; Tran et al., 2015, 2013b).”
BackgroundA Current Perspective on Daptomycin for the Clinical Microbiologist
Humphries, R. M., Pollett, S., & Sakoulas, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-13 · Cited by 239 · see citing works
“faecalis isolate with a daptomycin-susceptible MIC of 4 g/ml but a mutated liaF allele introduced via allelic exchange was daptomycin tolerant in vitro (80).”
BackgroundMechanisms of drug resistance: daptomycin resistance
Tran, T. T., Munita, J. M., & Arias, C. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12948 · Cited by 236 · see citing works
Self-citationMechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and EnterococciPreprint
Miller, W. R., Bayer, A. S., & Arias, C. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026997 · Cited by 229 · see citing works
“Further, this same change was noted to abolish the bactericidal action of DAP in vitro (loss of a three log10 decrease in time–kill curve colony counts), despite the MIC being within the “susceptible” range (Munita et al. 2013).”
BackgroundSelf-citationTran, T. T., Panesso, D., Mishra, N. N., Mileykovskaya, E., Guan, Z., Munita, J. M., Reyes, J., Diaz, L., Weinstock, G. M., Murray, B. E., et al. (2013) · mBio · doi:10.1128/mbio.00281-13 · Cited by 192 · see citing works
“Using an allelic replacement strategy, we showed that deletion of isoleucine in position 177 of the putative LiaF (lipid II-interacting-antibiotic protein) was sufficient to decrease DAP susceptibility (although still below the clinical breakpoint) and led to DAP tolerance, abolishing the in vitro bactericidal activit…”
MethodSelf-citationResistance in Vancomycin-Resistant Enterococci
Miller, W. R., Murray, B. E., Rice, L. B., & Arias, C. A. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.08.004 · Cited by 176 · see citing works
“Indeed, clinical failures of DAP have been associated with this scenario (101), and isolates with DAP MICs in the 3 to 4 μg/mL range are associated with mutations in the LiaFSR system (104).”
BackgroundSelf-citationWhole-Genome Analyses of Enterococcus faecium Isolates with Diverse Daptomycin MICs
Díaz, L., Tran, T. T., Munita, J. M., Miller, W. R., Rincón, S., Carvajal, L. P., Wollam, A., Reyes, J., Panesso, D., Rojas, N. L., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02686-14 · Cited by 138 · see citing works
“faecalis indicated that a single liaF mutation abolished the in vitro bactericidal activity of DAP (DAPtolerant phenotype) (13) but did not increase the MIC above the breakpoint.”
BackgroundMethodInfluentialSelf-citationVancomycin-Resistant Enterococci
Miller, W. R., Murray, B. E., Rice, L. B., & Arias, C. A. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.02.006 · Cited by 124 · see citing works
Self-citationAdaptation of Enterococcus faecalis to Daptomycin Reveals an Ordered Progression to Resistance
Miller, C. A., Kong, J., Tran, T. T., Arias, C. A., Saxer, G., & Shamoo, Y. E. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01473-13 · Cited by 103 · see citing works
“Additional genomic studies on DAP resistance in other enterococci also observed mutations in the liaFSR stress response pathway, as well as many other genes, whose roles and relative importance remain uncertain (7, 8, 10, 11).”
BackgroundSelf-citationReyes, J., Panesso, D., Tran, T. T., Mishra, N. N., Cruz, M. R., Munita, J. M., Singh, K. V., Yeaman, M. R., Murray, B. E., Shamoo, Y., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu602 · Cited by 94 · see citing works
“Our previous studies [7–10] focused on the mechanisms of DAP resistance in enterococci.”
BackgroundResultSelf-citationStructure–Activity Relationships of Daptomycin Lipopeptides
Karas, J. A., Carter, G. P., Howden, B. P., Turner, A. M., Paulin, O. K. A., Swarbrick, J., Baker, M. A., Li, J., & Velkov, T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00780 · Cited by 81 · see citing works
Mechanisms of antimicrobial resistance among hospital-associated pathogens
Khan, A., Miller, W. R., & Arias, C. A. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1456919 · Cited by 77 · see citing works
“It was also sufficient to abolish DAP bactericidal activity, despite the MIC being below the breakpoint [170].”
BackgroundSelf-citationMunita, J. M., Mishra, N. N., Alvarez, D., Tran, T. T., Diaz, L., Panesso, D., Reyes, J., Murray, B. E., Adachi, J. A., Bayer, A. S., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu642 · Cited by 70 · see citing works
“Time-kill assays with and without DAP (5-fold the MIC) were performed as described elsewhere [6].”
MethodSelf-citationWhat’s New in the Treatment of Enterococcal Endocarditis?
Nigo, M., Munita, J. M., Arias, C. A., & Murray, B. E. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0431-z · Cited by 52 · see citing works
Self-citationHarp, J. R., Saito, H. E., Bourdon, A. K., Reyes, J., Arias, C. A., Campagna, S. R., & Fozo, E. M. (2016) · Applied and Environmental Microbiology · doi:10.1128/aem.00933-16 · Cited by 48 · see citing works
“It is thought that this mutation increased the expression of LiaSR, activating the damage response pathway and effectively abolishing the bactericidal activity of the antibiotic (28, 29).”
BackgroundSelf-citationKebriaei, R., Rice, S., Singh, K. V., Stamper, K. C., Dinh, A. Q., Ríos, R., Díaz, L., Murray, B. E., Munita, J. M., Tran, T. T., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00315-18 · Cited by 44 · see citing works
“faecium (DAP MIC, 2 mg/liter) that harbors the T120S and W73C substitutions in LiaS and LiaR, respectively, and has been described previously (26, 42, 43).”
MethodSelf-citationDaptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci
Munita, J. M., Murray, B. E., & Arias, C. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.08.002 · Cited by 43 · see citing works
Self-citationHindler, J. A., Wong‐Beringer, A., Charlton, C. L., Miller, S. A., Kelesidis, T., Carvalho, M., Sakoulas, G., Nonejuie, P., Pogliano, J. A., Nizet, V., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05077-14 · Cited by 43 · see citing works
“These isolates harbor point mutations in the liaFSR genes, which encode a three-component regulatory system involved in cell membrane stress response (10, 11).”
BackgroundInfluentialMcElvania, E., Thomas, B. S., Ewald, G. A., Lawrence, S. J., & Burnham, C. D. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2188-6 · Cited by 43 · see citing works
“Daptomycin resistance in enterococci has been linked with mutations in genes liaF, yycG, and gdpD, which regulate cell membrane homeostasis, cell membrane phospholipid metabolism, and bacterial stress response [18–21].”
Panesso, D., Reyes, J., Gaston, E. P., Deal, M., Londoño, A., Nigo, M., Munita, J. M., Miller, W. R., Shamoo, Y. E., Tran, T. T., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01073-15 · Cited by 40 · see citing works
“9% saline solution before plating (11, 26, 27).”
BackgroundSelf-citationSnyder, A. D. H., Werth, B. J., Nonejuie, P., McRoberts, J. P., Pogliano, J., Sakoulas, G., Yim, J., Singh, N. B., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00687-16 · Cited by 41 · see citing works
Miller, W. R., Tran, T. T., Díaz, L., Ríos, R., Khan, A., Reyes, J., Prater, A. G., Panesso, D., Shamoo, Y. E., & Arias, C. A. (2018) · Molecular Microbiology · doi:10.1111/mmi.14193 · Cited by 37 · see citing works
Self-citationClinical Outcomes of Daptomycin for Vancomycin-resistant Enterococcus Bacteremia
Moise, P. A., Sakoulas, G., McKinnell, J. A., Lamp, K. C., DePestel, D. D., Yoon, M., Reyes, K., & Zervos, M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.04.008 · Cited by 40 · see citing works
“393 Diabetes 66 (25) 56 (25) 10 (27) 0.”
Davlieva, M. G., Shi, Y., Leonard, P. G., Johnson, T. A., Zianni, M. R., Arias, C. A., Ladbury, J. E., & Shamoo, Y. E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv321 · Cited by 39 · see citing works
Self-citationSaito, H. E., Harp, J. R., & Fozo, E. M. (2017) · Applied and Environmental Microbiology · doi:10.1128/aem.01633-17 · Cited by 39 · see citing works
The Making and Taking of Lipids
Fozo, E. M., & Rucks, E. A. (2016) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2016.07.001 · Cited by 38 · see citing works
Enterococcus Species, Streptococcus gallolyticus Group, and Leuconostoc Species
Arias, C. A., & Murray, B. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00202-2 · Cited by 37 · see citing works
Self-citationWang, G., Yu, F., Lin, H. C., Murugesan, K., Huang, W., Hoss, A. G., Dhand, A., Lee, L. Y., Zhuge, J., Yin, C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209785 · Cited by 34 · see citing works
Coyne, A. J. K., Stamper, K. C., Kebriaei, R., Holger, D. J., Ghali, A. E., Morrisette, T., Biswas, B., Wilson, M., Deschenes, M. V., Canfield, G. S., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11091175 · Cited by 37 · see citing works
“HOU503 is a vancomycin-resistant (VAN MBIC = 2 μg/mL), DAP-susceptible dose dependent (SDD) (DAP MBIC = 32 μg/mL) clinical strain that harbors T120A and W73C substitutions in LiaS and LiaR, respectively [35,36].”
BackgroundSelf-citationJahanbakhsh, S., Singh, N. B., Yim, J., Kebriaei, R., Smith, J. R., Lev, K. L., Tran, T. T., Rose, W. E., Arias, C. A., & Rybak, M. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02074-19 · Cited by 32 · see citing works
“HOU503 (DAP MIC 2 g/ml) harbors the T120S and W73C substitutions in LiaS and LiaR, respectively (33, 47), whereas S447 lacks substitutions in the LiaFSR system (48).”
BackgroundSelf-citationGolla, R. M., Mishra, B., Dang, X., Narayana, J. L., Li, A., Xu, L., & Wang, G. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00112 · Cited by 29 · see citing works
Rincón, S., Panesso, D., Díaz, L., Carvajal, L. P., Reyes, J., Munita, J. M., & Arias, C. A. (2014) · Biomédica · doi:10.7705/biomedica.v34i0.2210 · Cited by 35 · see citing works
Self-citationCosta, E. M., Silva, S., Veiga, M., Vicente, S., Tavaria, F. K., & Pintado, M. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.06.087 · Cited by 25 · see citing works
Targeting cell membrane adaptation as a novel antimicrobial strategy
Tran, T. T., Miller, W. R., Shamoo, Y. E., & Arias, C. A. (2016) · Current Opinion in Microbiology · doi:10.1016/j.mib.2016.07.002 · Cited by 24 · see citing works
“faecalis and abolished DAP bactericidal activity in time-kill assays [27, 31].”
BackgroundSelf-citationMechanisms of Antibacterial Resistance
Oliveira, K. D. S., de Lima, L. A., Cobacho, N. B., Dias, S. C., & Franco, O. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803642-6.00002-2 · Cited by 23 · see citing works
Kebriaei, R., Stamper, K. C., Singh, K. V., Khan, A., Rice, S., Dinh, A. Q., Tran, T. T., Murray, B. E., Arias, C. A., & Rybak, M. J. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa319 · Cited by 20 · see citing works
Self-citationMurray, B. E., Arias, C. A., & Nannini, E. C. (2015) · Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases · doi:10.1016/b978-1-4557-4801-3.00030-8 · Cited by 20 · see citing works
Self-citationCoyne, A. J. K., Stamper, K. C., Ghali, A. E., Kebriaei, R., Biswas, B., Wilson, M., Deschenes, M. V., Tran, T. T., Arias, C. A., & Rybak, M. J. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00340-23 · Cited by 23 · see citing works
Self-citationSusceptibilidad antimicrobiana en Chile 2012
Marcela Cifuentes, D., Silva, F., García, P., Bello‐Toledo, H., Isabel Briceño, L., Calvo-A, M., & Labarca, J. A. (2014) · Revista chilena de infectología · doi:10.4067/s0716-10182014000200002 · Cited by 17 · see citing works
Taylor, S. D., & Moreira, R. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.04.003 · Cited by 16 · see citing works
[Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].
Rincón, S., Panesso, D., Díaz, L., Carvajal, L. P., Reyes, J., Munita, J. M., & Arias, C. A. (2014) · PubMed · doi:10.1590/s0120-41572014000500022 · Cited by 16 · see citing works
Self-citationEndocarditis Caused by Resistant Enterococcus: An Overview
Reyes, K., & Zervos, M. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0348-y · Cited by 15 · see citing works
The LiaFSR Transcriptome Reveals an Interconnected Regulatory Network in Group A Streptococcus
Sanson, M. A., Vega, L. A., Shah, B. J., Regmi, S., Cubria, M. B., Horstmann, N., Shelburne, S. A., & Flores, A. R. (2021) · Infection and Immunity · doi:10.1128/iai.00215-21 · Cited by 15 · see citing works
“In addition, alteration of LiaFSR activity has previously been shown to affect antimicrobial susceptibility in Enterococcus (14, 15).”
BackgroundBacterial Stress Responses as Determinants of Antimicrobial Resistance
Fruci, M., & Poole, K. (2016) · doi:10.1002/9781119004813.ch10 · Cited by 15 · see citing works
Axell‐House, D. B., Simar, S. R., Panesso, D., Rincón, S., Miller, W. R., Khan, A., Pemberton, O. A., Valdez, L., Nguyen, A. H., Hood, K. S., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01069-23 · Cited by 12 · see citing works
“The discrepancies between activation of cell membrane stress response and DAP susceptibility have been previously described by our group in E. faecalis (31).”
BackgroundResultSelf-citationLin, Y., Sanson, M. A., Vega, L. A., Shah, B. J., Regmi, S., Cubria, M. B., & Flores, A. R. (2020) · mBio · doi:10.1128/mbio.01804-20 · Cited by 12 · see citing works
Antimicrobial tolerance and its role in the development of resistance: Lessons from enterococci
Darnell, R. L., Paxie, O., Rose, F. O. T., Morris, S. M., Krause, A. L., Monk, I. R., Smith, M. J. B., Stinear, T. P., Cook, G. M., & Gebhard, S. (2022) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2022.06.004 · Cited by 11 · see citing works
Tymoszewska, A., Szylińska, M., & Aleksandrzak‐Piekarczyk, T. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00343-23 · Cited by 9 · see citing works
Belley, A. C., Séguin, D. L., Arhin, F. F., & Moeck, G. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01265-17 · Cited by 8 · see citing works
“faecalis isolate was shown to cause a three-fold increase its 134 daptomycin MIC and abolished the bactericidal activity of the drug (26).”
BackgroundRincón, S., Panesso, D., Miller, W. R., Singh, K. V., Cruz, M. R., Khan, A., Dinh, A. Q., Díaz, L., Ríos, R., Shamoo, Y. E., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz131 · Cited by 8 · see citing works
“None of the genes have been previously associated with DAP resistance [12, 13, 16, 17], with the exception of those related to sugar phosphotransferase systems [36].”
BackgroundSelf-citationMechanisms of antibacterial drug resistance and approaches to overcome
Valsamatzi-Panagiotou, A., Traykovska, M., & Prof. Robert Penchovsky, D. R. N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818480-6.00002-3 · Cited by 7 · see citing works
Enterococcal Infections in Adults
Reyes, K., Zervos, M., & John, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_3 · Cited by 4 · see citing works
Modern View on Enterococcus faecalis and Enterococcus faecium Resistance Mechanisms to Antibiotics
Сергеевна, К. Т., & Зайцева, Е. А. (2021) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2020-65-11-12-38-48 · Cited by 4 · see citing works
Casey, R. L., Silverberg, A. L., Marty, M. T., & Hines, K. M. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6c00092 · Cited by 3 · see citing works
Colomer‐Winter, C., Nair, Z. J., Chua, J., Jabli, S., Roch, M., Cazenave‐Gassiot, A., Sierra, R., Andrey, D. O., Chng, S., & Kline, K. A. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2532437123 · Cited by 1 · see citing works
Darnell, R. L., Knottenbelt, M. K., Rose, O. E., Cleary, C. S. B., Rose, F. O. T., Hodgkinson, H., Wu, Y., Hussein, M. H., Velkov, T., Gebhard, S., et al. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00629-25 · Cited by 1 · see citing works
“Taken together, these data suggest that while both J4 and the MvaD A273E single variant reconstruction of the A8 mutant showed hyperactive signaling via the CroRS pathway, the J4 mutant additionally contains a partially de-repressed LiaSR signaling system, most likely due to the Ile171 insertion in the LiaF repressor.”
InfluentialFernández-Alonso, J. A., Pedrosa-Corral, I., Franco-Acosta, A., Ruíz, M. E., Aznarte-Padial, P., Navarro‐Marí, J. M., & Fernández, J. G. (2023) · ANALES RANM · doi:10.32440/ar.2023.140.03.rev06 · Cited by 1 · see citing works
Origin ofde novodaptomycin non susceptible enterococci
Kelesidis, T. (2015) · World Journal of Clinical Infectious Diseases · doi:10.5495/wjcid.v5.i2.30
Re-emerging Bacterial Infections of the Skin
Skopicki, N., Nguyen, A. H., Dokic, Y., Johnson, E. K., Bhamidipati, D. R., & Nguyen, H. P. (2021) · Updates in clinical dermatology · doi:10.1007/978-3-030-68321-4_3
Smith, J. R., Claeys, K. C., Zasowski, E. J., Yim, J., & Rybak, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_21
Zhivoderova, A., & Samoylenko, V. S. (2023) · International Journal of Veterinary Medicine · doi:10.52419/issn2072-2419.2023.4.78
Nguyen, A. H., Axell‐House, D. B., Miller, W. R., & Arias, C. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00046-0
Self-citationCombined Antimicrobial Therapy for Infective Endocarditis
Gomez-Villegas, S. I., Miller, W. R., & Arias, C. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65839-6_16
Self-citationCurrent Management of Serious Infections due to Vancomycin-resistant Enterococci
Gomez-Villegas, S. I., Wh, M., & Arias, C. A. D. (2026) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.12.004
Self-citationSaturated fatty acids enhance daptomycin activity in a Fak-dependent manner in enterococci
Maharjan, S., Getty, T. A., Dickens, Q., Hughes, A. L., Rundle, J., & Fozo, E. M. (2026) · Microbiology · doi:10.1099/mic.0.001751
“Sequence and experimental evidence demonstrated that a mutation in the LiaFSR signalling system was the primary reason for the high drug resistance [47, 48].”
- Authors
- Munita, J. M., Tran, T. T., Diaz, L., Panesso, D., Reyes, J., Murray, B. E., & Arias, C. A.
- Affiliations
- Universidad del Desarrollo (CL)
- University of Houston (US)
- Laboratory for Antimicrobial Research, University of Texas Medical School at Houston, Houston, Texas, USA
- Universidad El Bosque (CO)
- The University of Texas Health Science Center at Houston (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-06
- Volume
- 57
- Issue
- 6
- Pages
- 2831-2833
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3716119
- OpenAlex
- W2163046019
- Cited by
- 70
- References
- 12
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 7 · 2019: 1 · 2018: 5 · 2017: 5 · 2016: 10 · 2015: 8 · 2014: 10 · 2013: 4 · 2012: 1
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Repositorio Institucional Universidad El Bosque (submittedVersion)
- Funders
- Astellas Pharma
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R00 AI72961, R01AI093749, R00AI072961, NIH R01 AI047923, R01AI047923)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- daptomycin, vancomycin-resistant Enterococcus faecalis, antibiotic tolerance, bactericidal activity, lipopeptide antibiotics
- MeSH terms
- Anti-Bacterial Agents, Bacterial Proteins, Cell Wall, Codon, Humans, Microbial Sensitivity Tests, Stem Cells, Vancomycin, Enterococcus faecium, Sequence Deletion, Sequence Analysis, DNA, Daptomycin, Vancomycin Resistance, Drug Resistance, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
